Skip to main content

Table 1

From: Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania

Percent HCV RNA not detected

Week 4 (RVR)

Week 4+12 (eRVR)

Week 12

Treatment-naïve (n=30)

73%

70%

93%

Prior relapser (n=156)

85%

81%

94%

Prior partial responder (n=6)

100%

83%

83%

Prior null responder (n=15)

80%

73%

80%

Overalla (n=209)

83%

79%

92%

  1. aincludes 2 patients with prior virological break-through, not in four categories above